Editorial: treating hepatorenal syndrome-a window and the views. Authors' reply
Aliment Pharmacol Ther
.
2020 Sep;52(5):897.
doi: 10.1111/apt.15981.
Authors
Andrew S Allegretti
1
,
Khurram Jamil
2
,
Kevin Moore
3
Affiliations
1
Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
2
Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA.
3
UCL Institute of Liver and Digestive Health, Royal Free Hospital, University College London, London, UK.
PMID:
32852830
DOI:
10.1111/apt.15981
No abstract available
Publication types
Editorial
Comment
MeSH terms
Hepatorenal Syndrome* / drug therapy
Humans
Terlipressin*
Vasoconstrictor Agents / therapeutic use
Substances
Vasoconstrictor Agents
Terlipressin